Categorynews

Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019

May 2, 2019 Off By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™
Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a
leading developer of investigational ribonucleic acid interference
(RNAi) therapeutics, today announced that the Company will release its
first quarter 2019 financial results after market close on Thursday, May
9, 2019.

Management will host a conference call at 4:30 p.m. ET that day to
discuss the Company’s financial results and provide a general business
update. The conference call will be webcast live via the Internet and
will be available on the “Investors & Media” section of the Dicerna
website, www.dicerna.com.
The webcast will also be archived on the Company’s website.

The call can also be accessed by dialing (855) 453-3834 or +1 (484)
756-4306 (international) and referencing conference ID 4749943 prior to
the start of the call. After the conference call, a replay will be
available for seven days. To access the replay, please dial (855)
859-2056 or (404) 537-3406 and refer to conference ID 4749943.

About Dicerna™ Pharmaceuticals, Inc.

Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company focused
on the discovery and development of innovative, subcutaneously delivered
RNAi-based therapeutics for the treatment of diseases involving the
liver, including rare diseases, chronic liver diseases, cardiovascular
diseases and viral infectious diseases. Dicerna is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad pipeline in
these core therapeutic areas, focusing on target genes where connections
between these genes and diseases are well understood and documented.
Dicerna intends to discover, develop and commercialize novel
therapeutics either on its own or in collaboration with pharmaceutical
partners. Dicerna has strategic collaborations with Eli Lilly and
Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim
International GmbH. For more information, please visit www.dicerna.com.